共 42 条
- [21] A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor responseNATURE CANCER, 2020, 1 (11) : 1054 - +Lameris, RoelandShahine, AdamPellicci, Daniel G.Uldrich, Adam P.Gras, StephanieLe Nours, JeromeGroen, Richard W. J.Vree, JanaReddiex, Scott J. J.Quinones-Parra, Sergio M.Richardson, Stewart K.Howell, Amy R.Zweegman, SonjaGodfrey, Dale I.de Gruijl, Tanja D.Rossjohn, Jamievan der Vliet, Hans J.
- [22] A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor responseNature Cancer, 2020, 1 : 1054 - 1065Roeland LamerisAdam ShahineDaniel G. PellicciAdam P. UldrichStephanie GrasJérôme Le NoursRichard W. J. GroenJana VreeScott J. J. ReddiexSergio M. Quiñones-ParraStewart K. RichardsonAmy R. HowellSonja ZweegmanDale I. GodfreyTanja D. de GruijlJamie RossjohnHans J. van der Vliet
- [24] SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (10)Kamikawa, TakayukiKimura, NaokiIshii, ShinyaMuraoka, MasaruKodama, TatsushiTaniguchi, KenjiYoshimoto, MoeMiura-Okuda, MomokoUchikawa, RyoKato, ChieShinozuka, JunkoAkai, ShoNaoi, SotaroTomioka, NanamiNagaya, NishikiPang, Chai LingGarvita, GuptaFeng, ShuShimada, MeiKamata-Sakurai, MikaAburatani, HiroyukiKitazawa, TakehisaIgawa, Tomoyuki
- [25] CRPA1A2: A novel TCR-based T-cell engager targeting MAGEA1-positive solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Xie, XingwangDong, J.Bi, JingleiZhai, JiahuiYan, BaoqiLi, YonghongWang, JianghuaZhu, Yaping
- [26] CB-839, a novel potent and selective glutaminase inhibitor, has broad antiproliferative activity in cell lines derived from both solid tumors and hematological malignanciesCANCER RESEARCH, 2014, 74 (19)Parlati, FrancescoDemo, Susan D.Gross, Matthew I.Janes, Julie R.Lewis, Evan R.MacKinnon, Andy L.Rodriguez, Mirna L. M.Shwonek, Peter J.Wang, TaotaoYang, JinfuZhang, DongZhao, FrancesBennett, Mark K.
- [27] Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumorsONCOIMMUNOLOGY, 2023, 12 (01):Ding, JianGuyette, SarahSchrand, BrettGeirut, JessicaHorton, HollyGuo, GuangwuDelgoffe, GregMenk, AshleyBaeuerle, Patrick A.Hofmeister, RobertTighe, Robert
- [28] HER2-XPAT, a novel protease-activatable T-cell engager (TCE) with potent T-cell activation and efficacy in solid tumors and large safety margins in non-human primate (NHP).CANCER RESEARCH, 2021, 81 (13)Cattaruzza, FioreNazeer, AyeshaLange, ZacharyKoski, CaitlinHammond, MikhailTo, MiltonYeung, PeteLam, SharonDerynck, Mika K.Irving, BryanSchellenberger, Volker
- [29] FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor ActivityCLINICAL CANCER RESEARCH, 2020, 26 (13) : 3333 - 3344Kraman, MatthewFaroudi, MustaphaAllen, Natalie L.Kmiecik, KatarzynaGliddon, DanielSeal, ClaireKoers, AlexanderWydro, Mateusz M.Batey, SarahWinnewisser, JuliaYoung, LesleyTuna, MihribanDoody, JacquelineMorrow, MichelleBrewis, Neil
- [30] Anti-GPC3 TRAB, a first-in-class T cell-redirecting bispecific antibody targeting glypican-3 with potent in vitro and in vivo antitumor efficacy against solid tumorsCANCER RESEARCH, 2016, 76Kinoshita, YasukoIshiguro, TakahiroSano, YujiAzuma, YumikoTsunenari, ToshiakiOno, NatsukiKayukawa, YokoUeda, OtoyaWada, Naoko A.Hino, HiroshiJishage, KoichiShiraiwa, HirotakeKamata-Sakurai, MikaNezu, JunichiEndo, Mika